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Purpose/Objective: We retrospectively analyzed our five 
years experience with patient-specific VMAT QA using the 
PTW seven29/Octavius system and reported our institutional 
guidelines and action limits for VMAT delivery.  
Materials and Methods: Since June 2009, 1001 patients were 
treated with Elekta VMAT technique at our institution. 
Treatment plans were re-grouped according to treatment 
technique and disease sites: (1) 437 patients with high-
modulated complex treatments for head-neck, rectal, 
endometrial, brain tumours and other sites, all optimized 
with Masterplan Oncentra TPS with Simultaneous Integrated 
Boost strategy in dual-arc modality; (2) 248 patients with 
prostate tumours and (3) 316 patients with bone, liver, lung, 
abdominal and pelvic metastasis treated with high-dose 
extracranial stereotactic radiotherapy (SBRT). Group 2/3 
plans were optimized with anatomy-based Ergo++ TPS and 
treated with one arc. The absolute doses were measured 
utilizing the PTW Seven29 ion-chamber array and the 
Octavius phantom. VMAT plans were recalculated on 
phantoms representing the Octavius geometry and density; 
for each arc the doses were measured both on coronal and 
sagittal planes, for a total of 2876 measurements (in groups 1 
and 2/3, each plan underwent four and two measurements, 
respectively). Agreement of measured and predicted doses 
were evaluated using 3%(global)/3mm γ-analysis. Three 
scalar metrics were evaluated for each measurement: (a) 
percentage of points with gamma value less than one (Pg<1), 
(b) mean gamma (γmean), and (c) maximum gamma (γmax). 
Gamma results were evaluated according to treatment 
technique and disease sites and reported for each arc 
individually and on a per patient-basis. 
Results: Table 1 shows the overall γ-analysis results for all 
patients with associated confidence limits. γ pass-rate values 
significantly depend on plan complexity. For the patients in 
group (1), average Pg<1, γmean and γmax were 94.8% ± 3.8%, 0.39 
± 0.08 and 1.83 ± 0.55, respectively. These values reached 
99.1% ± 1.9%, 0.38 ± 0.08 and 0.99 ± 0.25 values in group (2) 
and 98.3% ± 2.7%, 0.32 ± 0.09 and 1.13 ± 0.45 values in group 
(3). On a per-patient basis, our local confidence limits for Pg<1 
were determined to be 10.0%, 4.0%, and 6.6%, for patients in 
group 1, 2 and 3, respectively. 
 
 
 
Conclusions: This comprehensive study shows that PTW 
seven29/Octavius system allows a reliable and accurate 
dosimetric procedure for VMAT QA, benefiting from all the 
advantages of ionization chamber absolute dosimetry. 
Despite the increased complexity in VMAT treatments, our 
local confidence limits were comparable to those of AAPM TG 
119. 
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Purpose/Objective: VMAT delivers radiation via dynamic 
multileaf collimator (MLC) motion, and allows for variable 
dose rates, gantry speed modulation, and collimator rotation. 
It is, therefore, patient-specific quality assurance (QA) for 
VMAT plans is important in confirming dose distribution. The 
COMPASS® system allows for 3D dosimetric quality assurance 
using MatriXX-specific software and the MatriXX mounted to 
the gantry with a gantry angle sensor. In this study, the 
retrospective investigation of the QA results using COMPASS 
for head and neck (H&N) VMAT cases. 
Materials and Methods: VMAT patient plans were delivered 
to the MatriXX and used to verify the 3D dose distribution 
calculated by COMPASS. QA results of 65 head and neck 
patients which were treated in our clinic with 
TrueBeam/TrubeamSTX machine consist of the 
nasopharyngeal, larynx and oral cavity tumors were analyzed. 
Compass system with MatriXX can provide an accurate three-
dimensional quantitative analysis of dose delivery. Dose 
distribution and 3D anatomical site dose differences using 
DVH were evaluated by comparing the measurements and the 
treatment planning system (TPS) calculations by using AAA 
algorithm at the Eclipse TPS. Furthermore, the investigation 
of the TPS and COMPASS dose calculation based on the 
Collapse Cone Algorithm was assessed. The COMPASS and the 
measurement dose distributions agreement was tried o obtain 
with that of a treatment planning system by gamma analysis 
(criteria; 3 mm/3%)a and the volumetric results of the 
critical organs such as spinalcord was evaluated by average 
dose value with 3% criteria. 
Results: Compass system was very sensitive to the MLC and 
dose error caused by machine. This system allows to asses 3D 
anatomical based dose difference between measurement and 
planning dose. We found that except 5 cases inside the data 
sets the relative dose differences agreement within the dose 
volume criteria for spinalcord. All parotid glands dose 
differences were inside the dose acceptance criteria except a 
case which shows 4,03%. For all cases, CTV and GTV dose 
agreement was archived inside the gamma criteria. 
Conclusions: The COMPASS system can be expected to be 
used for traditional QA methods in clinical routine for QA of 
VMAT plans. The Compass allows anatomical dose distribution 
evaluation to decide acceptable treatment plan. 
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